{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:39:32Z","timestamp":1787593172380,"version":"build-2736575974"},"reference-count":47,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>On 28 July 2021, Semglee (insulin glargine\u2010yfgn) was approved by the U.S. Food and Drug Administration as the first interchangeable biosimilar to the reference product Lantus (insulin glargine) for treating diabetes mellitus. This study used the FDA Adverse Event Reporting System to identify reporting safety signals of Lantus and Semglee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Adverse event (AE) reports were organized into high\u2010level group terms (HLGTs) using the Medical Dictionary for Regulatory Activities (MedDRA). Disproportionality analysis, including reporting odds ratio (ROR) and empirical Bayesian geometric mean (EBGM), was performed to detect safety signals for serious AE, death, hospitalization, top 6 HLGTs, and specific AEs on products' FDA prescription labels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both products showed no significant safety signal of serious AE, death, or hospitalization. Lantus exhibited significant safety signals for device issues (ROR\u2009=\u20091.3, 95% confidence interval [CI]\u2009=\u20091.2\u20131.4; EBGM\u2009=\u20091.3, 90% CI\u2009=\u20091.2\u20131.3), medication errors and other product use errors and issues (ROR\u2009=\u20092.8, 95% CI\u2009=\u20092.7\u20132.9; EBGM\u2009=\u20092.1, 90% CI\u2009=\u20092.0\u20132.1), metabolic, nutritional, and blood gas investigations (ROR\u2009=\u200911.7, 95% CI\u2009=\u200911.2\u201312.2; EBGM\u2009=\u20099.6, 90% CI\u2009=\u20099.3\u20139.9), hyperglycaemia (ROR\u2009=\u20092.7, 95% CI\u2009=\u20092.1\u20133.5; EBGM\u2009=\u20092.3, 90% CI\u2009=\u20091.9\u20132.8) and hypoglycaemia (ROR\u2009=\u20094.6, 95% CI\u2009=\u20093.6\u20135.8; EBGM\u2009=\u20093.7, 90% CI\u2009=\u20093.0\u20134.5). Semglee had significant safety signals for device issues (ROR\u2009=\u2009118.7, 95% CI\u2009=\u2009103.9\u2013135.7; EBGM\u2009=\u200922.8, 90% CI\u2009=\u200921.7\u201323.9), medication errors and other product use errors and issues (ROR\u2009=\u20093.4, 95% CI\u2009=\u20093.0\u20133.8; EBGM\u2009=\u20092.3, 90% CI\u2009=\u20092.1\u20132.4), metabolic, nutritional, and blood gas investigations (ROR = 3.0, 95% CI = 2.3\u20133.9; EBGM = 2.5, 90% CI = 2.0\u20133.1), product quality, supply, distribution, manufacturing, and quality system issues (ROR\u2009=\u20095.4, 95% CI\u2009=\u20094.6\u20136.3; EBGM\u2009=\u20094.4, 90% CI\u2009=\u20093.9\u20135.0), physical examination and organ system status topics (ROR\u2009=\u20092.6, 95% CI\u2009=\u20092.0\u20133.2; EBGM\u2009=\u20092.2, 90% CI\u2009=\u20091.9\u20132.7), weight gain (ROR\u2009=\u20093.6, 95% CI\u2009=\u20092.6\u20134.8; EBGM\u2009=\u20092.7, 90% CI\u2009=\u20092.1\u20133.5), weight loss (ROR\u2009=\u20092.0, 95% CI\u2009=\u20091.4\u20132.9; EBGM\u2009=\u20091.7, 90% CI\u2009=\u20091.2\u20132.2), and lipodystrophy (ROR\u2009=\u2009146.0, 95% CI\u2009=\u200996.1\u2013221.8; EBGM\u2009=\u2009116.0, 90% CI\u2009=\u200981.7\u2013160.8).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings identified significant post\u2010marketing safety signals of Lantus and Semglee. Longitudinal studies are warranted to verify these signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16491","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:55:04Z","timestamp":1748490904000},"page":"4480-4489","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Post\u2010marketing safety of Lantus and its interchangeable biosimilar Semglee in the United States: A disproportionality analysis using the\n                    <scp>FDA<\/scp>\n                    Adverse Event Reporting System (\n                    <scp>FAERS<\/scp>\n                    ) database"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2688-3958","authenticated-orcid":false,"given":"Lotanna","family":"Ezeja","sequence":"first","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison College of Pharmacy  Auburn Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes Research and Policy Auburn University Harrison College of Pharmacy  Auburn Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"e_1_2_12_2_1","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","author":"Committee, A.D.A.P.P","year":"2024","journal-title":"Diabetes Care"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2763"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxae105"},{"key":"e_1_2_12_5_1","unstructured":"U.S. Food & Drug Administration.Biosimilar and interchangeable biologics: more treatment choices. 2023. Accessed December 24 2024.https:\/\/www.fda.gov\/consumers\/consumer\u2010updates\/biosimilar\u2010and\u2010interchangeable\u2010biologics\u2010more\u2010treatment\u2010choices"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-020-00784-2"},{"key":"e_1_2_12_7_1","unstructured":"U.S. Food & Drug Administration.9 Things to know about biosimilars and interchangeable biosimilars. 2024. Accessed December 24 2024.https:\/\/www.fda.gov\/drugs\/things\u2010know\u2010about\/9\u2010things\u2010know\u2010about\u2010biosimilars\u2010and\u2010interchangeable\u2010biosimilars"},{"key":"e_1_2_12_8_1","unstructured":"The Center for Biosimilars.Biosimilar interchangeability: 9 things to consider. 2018. Accessed December 24 2024.https:\/\/www.centerforbiosimilars.com\/view\/biosimilar-interchangeability-9-things-to-consider"},{"key":"e_1_2_12_9_1","unstructured":"U.S. Food & Drug Administration.Biosimilar product information. 2025. Accessed February 15 2025.https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"e_1_2_12_10_1","unstructured":"U.S. Food & Drug Administration.Review and approval. 2022. Accessed January 23 2025.https:\/\/www.fda.gov\/drugs\/biosimilars\/review-and-approval"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(13)70001-6"},{"key":"e_1_2_12_12_1","first-page":"1","article-title":"ISMP list of high\u2010alert medications in acute care settings","volume":"29","author":"Institute for Safe Medication Practices (ISMP)","year":"2024","journal-title":"ISMP"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/PTS.0b013e3181990d51"},{"key":"e_1_2_12_14_1","unstructured":"U.S. Food & Drug Administration.Mylan Pharmaceuticals Inc. a Viatris Company issues voluntary nationwide recall of one batch of insulin glargine (insulin glargine\u2010yfgn) injection pens 100 units\/mL (U\u2010100) due to the potential of missing labels on some pens. 2022. Accessed January 2 2025.https:\/\/www.fda.gov\/safety\/recalls\u2010market\u2010withdrawals\u2010safety\u2010alerts\/mylan\u2010pharmaceuticals\u2010inc\u2010viatris\u2010company\u2010issues\u2010voluntary\u2010nationwide\u2010recall\u2010one\u2010batch\u2010insulin"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13322"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13495"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13904"},{"key":"e_1_2_12_18_1","unstructured":"U.S. Food & Drug Administration.FDA's adverse event reporting system (FAERS). November 8 2024. Accessed January 2 2025.https:\/\/www.fda.gov\/drugs\/surveillance\/fdas\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers"},{"key":"e_1_2_12_19_1","unstructured":"U.S. Food & Drug Administration.FDA adverse event reporting system (FAERS) public dashboard. 2023. Accessed January 2 2024.https:\/\/www.fda.gov\/drugs\/fdas\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\/fda\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\u2010public\u2010dashboard"},{"key":"e_1_2_12_20_1","unstructured":"Medical Dictionary for Regulatory Activities.MedDRA hierarchy. Accessed December 2 2025.https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy"},{"key":"e_1_2_12_21_1","unstructured":"U.S. Food & Drug Administration.Frequently asked questions (FAQs). Accessed February 16 2025.https:\/\/fis.fda.gov\/extensions\/FPD-FAQ\/FPD-FAQ.html#_Toc514144622"},{"key":"e_1_2_12_22_1","unstructured":"U.S. Food & Drug Administration.Purple book: database of licensed biological products. 2024. Accessed December 23 2024.https:\/\/purplebooksearch.fda.gov\/"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/03946320251327618"},{"key":"e_1_2_12_24_1","unstructured":"U.S. Food & Drug Administration.What is a serious adverse event?2023. Accessed January 2 2025.https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"e_1_2_12_25_1","unstructured":"MedDRA web\u2010based browser. 2019. Accessed January 2 2024.https:\/\/tools.meddra.org\/wbb\/"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_12_27_1","unstructured":"U.S. Food & Drug Administration.Data mining at FDA \u2013 white paper. 2018. Accessed January 2 2025.https:\/\/www.fda.gov\/science-research\/data-mining\/data-mining-fda-white-paper#_edn6"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.7967"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225060-00010"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02510.x"},{"key":"e_1_2_12_31_1","unstructured":"U.S. Food & Drug Administration.Questions and answers on biosimilar development and the BPCI act guidance for industry. 2021. Accessed January 22 2025.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/questions\u2010and\u2010answers\u2010biosimilar\u2010development\u2010and\u2010bpci\u2010act\u2010guidance\u2010industry"},{"key":"e_1_2_12_32_1","unstructured":"U.S. Food & Drug Administration.Drugs@FDA: FDA\u2010approved drugs. Accessed April 15 2025.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021081"},{"key":"e_1_2_12_33_1","unstructured":"U.S. Food & Drug Administration.Drugs@FDA: FDA\u2010approved drugs. Accessed April 16 2025.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761201"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16278"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2017.0011"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-0105.183264"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp\u2010journals\u201010071\u201024588"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.34.1.25"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-07033-8"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5212"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/00185787221095771"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v94i3.14117"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S282926"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1323867"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13533"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70548"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0225-0"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2025.01.002"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.16491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.16491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.16491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:16:50Z","timestamp":1787591810000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.16491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/dom.16491"],"URL":"https:\/\/doi.org\/10.1111\/dom.16491","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16491\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16491\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16491\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16491\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16491\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16491\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16491\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"2025-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}